ID4Pharma
June 23, 2026
Theater 4
Type: Company Presentation
Focus Area:
Oncology
ID4Pharma is a clinical-stage precision oncology biotech with first-in-class targeted therapeutics for hematologic malignancies, relapsed/refractory multiple myeloma (RRMM), a disease with unmet medical need. ID4 holds a global IP portfolio, has received FDA IND clearance, and is advancing toward first-in-human clinical studies.
ID4Pharma combines proprietary AI-enabled structure-based drug discovery, translational pharmacology, and precision oncology platform technologies, and the MOA has been published in leading journals, including Cell, Nat Comm, PNAS, Cells, Leukemia, etc.
Led by an experienced team with expertise in oncology drug discovery, translational medicine, regulatory strategy, and clinical development, ID4Pharma is pursuing strategic pharma partnerships, co-development collaborations, and regional/global licensing-out opportunities. ID4 is seeking Series A financing and VC investments to accelerate clinical development and expand its precision oncology pipeline.
Company HQ City:
BRIDGEVILLE, PA 15017 USA
Company HQ State:
PA
Company HQ Country:
United States
Year Founded:
2013
Lead Product in Development:
First-in-class targeted small-molecule therapeutic for relapsed/refractory multiple myeloma (RRMM), with an FDA IND-cleared program advancing toward first-in-human clinical studies.
Supported by a global patent portfolio exclusively licensed to ID4Pharma, based on technology invented by Dr. Sean Xie (Founder & CSO; Professor, University of Pittsburgh).
The lead program has demonstrated strong preclinical efficacy and favorable GLP toxicology, supporting clinical translation and regulatory advancement.
CEO
Sean Xie, MD, PhD, EMBA
Founder & CSO
Chairman of the Board, ID4Pharma | Professor of Unversity of Pittsburgh
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
1 FDA IND-cleared clinical-stage oncology asset and multiple earlier-stage platform opportunities available for partnership and licensing
When you expect your next catalyst update?
Q1–Q2 2027 (anticipated first-in-human FDA IND-approval study initiation; March–June 2027)
What is your next catalyst (value inflection) update?
Initiation of first-in-human (FIH) clinical study for the FDA IND-cleared RRMM program, including first patient dosing and progression through early Phase I milestones; advancement of strategic partnering and financing activities
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}